Emeishan Hongsheng Pharmaceutical Co.,Ltd was established in February, 2011, with a registered capital of RMB 50 million,covering an area of 18,320 square meters, construction area of 1,083 square meters, and total assets of more than RMB 72 million. The company is a national high-tech enterprise specializing in R & D, production and sales of Candesartan Cilexetil, Empagliflozin,Febuxostat,Linagliptin, Azilsartan and other intermediates. The company has been to adhering the concept that “Safety & environment is the base of enterprise survival; quality and innovation is the source of it's development. We are people-oriented and try to provide the best products and service for global customers.
Methyl 2-((tert-butoxycarbonyl)-amino)-3-nitrobenzoate